. These findings 56 make αSyn a focal point of biomarker and drug development programs for PD. 57
Several years before the first appearance of motor symptoms, many patients exhibit a variety of non-58 motor symptoms including constipation, sleep disorder, depression, and hyposmia [5] [6] [7] . Indeed, co-59 occurrence of some of these non-motor symptoms is coupled to elevated PD risk [8] [9] [10] [11] . Constipation is 60 an important non-motor feature of prodromal PD, with 28-61% of patients having exhibited 61 gastrointestinal dysfunction for several years during the prodrome 7, 10, 12 . Notably, αSyn-62 immunoreactive inclusions have been found in neurons of the submucosal plexus in people with PD 63 3, 13 . Taken together, this converging evidence suggests an early involvement of the enteric nervous 64 system (ENS) in the pathogenesis of PD. Already over a decade ago, Braak and colleagues 65 hypothesized that αSyn-immunoreactive inclusions first appear in the ENS and then gradually engage 66 the brainstem, including the dorsal motor nucleus of the vagus nerve and midbrain areas 3, 13 . Several 67 studies in preclinical models have demonstrated that αSyn pathology in the gut is associated with the 68 development of αSyn pathology in the brain [14] [15] [16] [17] [18] . It will be critical to determine factors that regulate 69 αSyn accumulation in the ENS and to understand whether the process underlying αSyn accumulation 70 in the gut can also lead to αSyn pathology in the brain. . Immune pathways are indeed activated in the brain and colon of PD cases 20, 21 . Also, several 74 genes associated with an increased PD risk have an immune system-related function 22 , and it was 75 recently proposed that PD heritability is not simply due to variation in brain-specific genes, but that 76 several cell types in different tissues might be involved 23 . Adding further genetic evidence supporting 77 that inflammation is involved in PD pathogenesis, a genome-wide association study identified 78 common genetic pathways linking PD and autoimmune disorders 24 . Most prominently, LRRK2, a 79 major genetic risk factor for PD also confers increased risk for developing inflammatory bowel 80 disease (IBD) 25 and is known to modulate the function of monocytes, macrophages and other immune 81 cells 26, 27 . Intriguingly, IBD is associated with an increased risk for developing PD and specifically 82 blocking the TNF pathway reduces this risk [28] [29] [30] [31] . This suggests that the intestinal immune 83 environment plays a role in triggering PD or facilitating the molecular events involved in the earliest 84 phases of the disease process 32 .
85
Here we tested the hypothesis that intestinal inflammation (e.g. colitis) triggers accumulation of αSyn 86 in the ENS and the subsequent development of αSyn pathology in the brain. We discovered that 87 patients with IBD exhibited increased αSyn accumulation in the submucosa of the colon. 88
Experimental forms of colitis in wild type and αSyn transgenic mice demonstrated that the type and 89 degree of inflammation regulates the amount of αSyn accumulation in the colon. Macrophage-related 90 signaling limited the extent of αSyn immunoreactivity. When αSyn transgenic mice were exposed to 91 experimental colitis at 3 months of age and then were aged normally up to 9 or 21 months, the 92 accumulation of aggregated αSyn in midbrain, including the SN, was much exacerbated in the 21-93 months age group, but not in the 9-months age group. These 21-month old mice also exhibited loss of 94 nigral tyrosine hydroxylase-immunoreactive neurons. Together, our data support a critical role for 95 intestinal inflammation in the initiation and progression of PD. 96
Page 7/43 while a marked destruction of the mucosa was induced when giving only DSS ( Figure 2D) . As 153 before, the DSS-exposed mice presented with increased accumulation of αSyn in the ganglia of the 154 submucosal plexus ( Figure 4A ). In contrast, we detected no change in αSyn load in the myenteric 155 plexus, consistent with lack of leukocyte infiltration in this part of the colonic wall ( Figure 4B) . 156
Despite the high dose, LPS-induced inflammation did not increase αSyn accumulation in the colonic 157 nervous plexuses (Figure 4C, D) . Notably, LPS and DSS resulted in a differential expression of 158 cytokines, and consistent with leukocyte recruitment, CCL2 was elevated in both ( Figure 4F, G) . In 159 the LPS paradigm, mRNA for IL-10 was markedly elevated, whereas DSS strongly increased IL-6 160 and also IL-1β but not IL-10. Together these results indicate that only certain types of local 161 inflammation increase the intracellular accumulation of αSyn in the colon. induced by an insertion of GFP (Cx3cr1-GFP knock-in mice) (Figure 4A, B) . The CX3CR1-CX3CL1 172 axis plays an important role in maintaining the function of the lamina propria macrophage population 173 of the gastrointestinal wall and lack of this signaling pathway in experimental colitis models may 174 either aggravate or ameliorate the induced pathology [35] [36] [37] . In our experiment, the area covered by 175 infiltrating leukocytes following exposure to DSS located to the mucosa and submucosa and was not 176 significantly higher in the Cx3cr1-deficient αSyn transgenic mice than in the Cx3cr1-competent mice 177 (Supplemental Figure 2A) . However, a significantly higher level of αSyn accumulated in the 178 submucosal plexus in αSyn transgenic mice lacking Cx3cr1 compared to αSyn transgenic mice 179 expressing Cx3cr1 (p = 0.001, two-way ANOVA with Tukey HSD post-hoc analysis; Figure 4A ). In 180 the myenteric plexus, we found no significant increase in αSyn accumulation in neither the αSyn 181 transgenic mice with normal Cx3cr1 nor the αSyn transgenic mice deficient in Cx3cr1, indicating 182 again a prominent role for the localization of leukocyte infiltration in the process of αSyn 183 accumulation in the submucosa ( Figure 4B) . Collectively, our results indicate a potential link 184 between monocyte/macrophage signaling and αSyn accumulation in ENS in this experimental IBD 185
model. 186 187
Systemic IL-10 ameliorates DSS-induced colitis and associated enteric αSyn accumulation in αSyn 188
transgenic mice 189
As mentioned above, LPS-induced colonic leukocyte infiltration did not result in increased 190 accumulation of αSyn in the ENS of the colon and that the main difference in cytokine expression 191 between the DSS and LPS paradigms was increased IL-10 expression in the LPS group (Figure 4) . 192
Interleukin-10 is an important regulator of monocytes/macrophages, and genetic ablation of IL-10 193 signaling or blocking IL-10 with specific antibodies has been reported to enhance DSS colitis 38, 39 . To 194 mimic the effect of higher levels of IL-10 in an acute model of DSS colitis (5% DSS, Figure 2C ), we 195 administered intravenously murine IL-10 (mIL10), which was recombinantly engineered onto two 196 different murine IgG variants to extend the half-life of mIL-10 in circulation (mIgG1(v1)-mIL10 and 197 mIgG1(v2)-mIL10, respectively). As described above, DSS induced a marked increase in leukocyte 198 infiltration and αSyn accumulation, and we found this to be similar in the untreated and control IgG 199 treated group (Figure 6A, B increasing dose paradigm. In order to allow for a full recovery from the chronic inflammation we then 220 left the mice for two months on normal drinking water and analyzed them at the age of 6 months 221 ( Figure 2C ). Because we also wanted to explore the effect of modulating monocytes/macrophages in 222 this chronic setting, an experimental arm with (Thy1)-h[A30P]αSyn transgenic mice crossed with 223 Cx3cr1-deficent mice was added. As expected, the area that is usually extensively covered by 224 leukocytes in the submucosal plexus of the acute DSS paradigm had returned to normal levels 225 following the two-month recovery period (Supplemental Figure 3A) . Remarkably, however, αSyn 226 accumulation in the ganglia of the submucosal plexus was still almost doubled when compared to 227 αSyn transgenic mice that were not exposed to DSS, and this was exacerbated in αSyn transgenic 228 mice deficient for Cx3cr1 (Supplemental Figure 3B) . This suggests that accumulation of αSyn is not The previously highlighted hypothesis by Braak and colleagues associates αSyn brain pathology in 235 PD with αSyn pathology in the ENS earlier in life 3, 41 . To assess development of brain αSyn pathology 236 and to link it again to IBD risk, we exposed 3-month old hemizygous (Thy1)-h[A30P]αSyn transgenic 237 mice to DSS or normal drinking water and after 23 days on this chronic increasing dose paradigm 238 returned all mice normal drinking water for the rest of their life ( Figure 2C) . We chose to use the 239 αSyn transgenic model rather than wild type mice for this study because we knew that the model 240 exhibits some αSyn brain pathology that develops slowly also under baseline conditions. After aging 241 up to 9 or 21 months (i.e. mice aged for an additional 6 or 18 months after the chronic DSS paradigm 242 at the age of 3 months, respectively), we analyzed brain regions for pathological αSyn (proteinase K 243 resistant, pSer129-αSyn immunoreactive inclusions). When we examined the αSyn transgenic mice 244 exposed to DSS at 3 months of age, left to live only until to 9 months, we found that they exhibited 245 extremely low levels of pathological αSyn inclusions in the brain, similar to the levels seen in 9 month 246 transgenic mice that were exposed to DSS at 3 months of age presented with pSer129-positive αSyn 252 pathology throughout various brain regions in a much exacerbated fashion than mice that were aged 253 up to 21 months without having experienced DSS colitis at young age. The significant aggravation of 254 αSyn pathology also in the substantia nigra (p≤0.01 in a negative-binomial mixed-effects model 255 adjusting for multiple comparisons performed over all brain areas) was accompanied by a significant 256 loss of tyrosine hydroxylase (TH) and Nissl positive cells at 21 months of age (p≤0.05, Student's T-257 test; Figure 8 ). Together, we found that DSS colitis at a young age caused an age-dependent 258 exacerbation of αSyn inclusion pathology and a loss of nigral dopaminergic neurons in the brains of 259 αSyn transgenic mice. 260
Discussion 261
Currently, there is no therapy for PD available to slow or stop its progression and an obstacle in the 262 quest to develop one is that we do not understand how the disease develops 43 . Intraneuronal 263 accumulation of αSyn (i.e. Lewy bodies and neurites) is a key neuropathological hallmark and the 264 distribution of Lewy pathology in postmortem brain is used for staging in PD 2, 44 . Accumulation of 265 αSyn has also been observed in the peripheral nervous system in PD, some individuals at risk of 266 developing the disease, and normal individuals [45] [46] [47] . Similar to this finding in people, αSyn-267 immunoreactive inclusions have also been detected in the ENS of a transgenic mouse model prior to 268 changes in the brain 48 . Based on preclinical models and postmortem pathology in various organs 269 including the brain, it has also been suggested that αSyn pathology propagates temporospatially in a 270 prion-like manner 3,44, [49] [50] [51] . However, the initial factors triggering αSyn aggregation are yet to be 271 pSer129-αSyn pathology in the midbrain, including the substantia nigra, and other brain regions and 287 an average decrease of 30-50% of TH-and Nissl-positive cells in the nigra. We chose to perform the 288 long-term experiments in αSyn transgenic rather than wild type mice. These particular αSyn 289 transgenic mice had previously been shown to slowly develop αSyn pathology in the brain 33 making 290 them ideal when asking the question whether transient colonic inflammation can aggravate brain 291 pathology in a genetically predisposed animal. In future long-term studies, we plan to address whether 292 αSyn pathology develops also in the brains of wildtype mice if they sustain transient experimental 293
IBD at a young age. In our experiments presented here, colitis in αSyn transgenic mice recapitulated 294 the accumulation of enteric αSyn which is proposed to occur in humans several years before PD 295 diagnosis 32 . Additionally, the subsequent age-related development of αSyn pathology together with 296 the loss of nigral dopaminergic neurons in the brain of αSyn transgenic mice mimicked a progression 297 of the disease similar to what is considered to occur in PD. 298
We established that a mechanism by which peripheral inflammation promotes αSyn accumulation in 299 the colon potentially involves monocytes and macrophages. Both peroral DSS and intraperitoneal LPS 300 administration provoked strong local immune reactions resulting in leukocyte infiltration into the 301 submucosa of the colon. The region of the colon which was inflamed contains the submucosal plexus 302 and is anatomically separated from the myenteric plexus by a thick circular muscle (Figure 2) . This 303 discrete localization of inflammation to the submucosa might explain why αSyn only accumulated in 304 the nerves of the submucosal plexus and not in the myenteric plexus of our mice given DSS. The 305 mechanism underlying how intraperitoneally administered LPS leads to submucosal leukocyte 306 infiltration probably involves the monocyte attractant chemokine CCL2 (Figure 4) , but the specifics 307 remain to be clarified 52 . Indeed, CCL2 was upregulated in the colon of our DSS model. However, in 308 contrast to intraperitoneal LPS, where infiltrating macrophages were present in discrete patches in the 309 colonic wall, DSS-related macrophage infiltration was distributed both in small groups and larger 310 randomly distributed patches of cells across the entire colonic submucosa. Also, perorally 311 administered DSS destroys the mucosa of the colon, similar to some forms of ulcerative colitis, . In this context, it is also notable that Crohn's patients present with increased enteric 321 αSyn expression 40 and even more striking that IBD patients on anti-TNF therapy have a reduced risk 322 of developing PD compared to IBD patients not given this treatment 29 . Here we demonstrate that 323 patients with IBD present with accumulation of αSyn in the ENS, as well as in infiltrating leukocytes 324 nearby. Notably, mucosal macrophages with intralysosomal αSyn content were previously described 325 in the intact human appendix 56 . These macrophages were in close proximity to the axonal varicosities 326 of the vermiform appendix which showed an enriched staining for αSyn in the mucosal plexus. 327
Furthermore, we recently found that the vermiform appendix contains aggregated and truncated αSyn 328 that has the propensity to seed aggregation of recombinant αSyn in vitro Perhaps the most striking finding in our study was that a single period of DSS-induced colitis at a 347 young age led to an exacerbation of αSyn pathology in the brain of αSyn transgenic mice much later 348 in life (Figure 7) . How does the severe αSyn inclusion pathology develop in the brain of these mice? 349
One hypothesis is that the brain αSyn pathology observed in this study could be due to direct effects suggest that pathogenic seeds can be transmitted via the vagal nerve 15, 66 . A role for the vagal nerve in 368 PD was also suggested by an epidemiological study indicating that vagotomy in a Danish population 369 is associated with decreased PD risk 67 , although this association has been challenged 68 . In the present 370 study, αSyn pathology was much more prominent in the reticular nucleus (including the vagal area) 371 and midbrain areas (compared to the rostral areas) at 18 months post DSS colitis. Although we did not 372 conduct the definitive experiment of cutting the vagal nerve, our data support the growing body of 373 evidence that the vagal nerve is involved in the accumulation of αSyn aggregates in the brain. 374
In summary, here we report that individuals with IBD exhibit αSyn accumulation in the colon 375 concomitant with infiltrating monocytes/macrophages positive for αSyn. We also show that αSyn 376 accumulates in the colon of αSyn transgenic and wildtype mice subjected to DSS colitis and that this 377 process is modulated by monocyte/macrophage-related signaling. We further demonstrate that chronic 378 DSS colitis in young αSyn transgenic mice leads to a markedly exacerbated accumulation of αSyn 379 aggregates in the brain when the mice age. In the same aged mice, the numbers of TH-and Nissl 380 positive neurons in the substantia nigra are reduced, suggestive of a neurodegenerative process. body-like features were filtered based on having a size between 12 and 50000 pixels and a minimal 487 intensity value greater than 300. The filtering step was included to exclude small background features 488 and macrophages (very large spots). The counts were then aggregated to the animal level by summing 489 the inclusion feature counts of all images per animal and then normalizing for (i.e. dividing by) the 490 number of images for a given animal. Upon exploratory data analysis two animals were excluded: one 491 mouse because it only had one image and another due it being an outlier, based on its infiltration score 492 and image data. 493
494

Blinding of experimenters 495
For analyses of colon and brain tissue on slides, a second individual assigned unique codes to 496 stained slides. Therefore, the experimenter conducted the analyses blinded to the identity of the 497 mice. For randomization of treatment groups see above. 498
499
Quantification of leukocytes infiltration 500
To determine the leukocyte covered area in the colon after LPS or DSS application, three adjacent 501 hematoxylin stained sections were quantified. Total area of colon sections and localizations of 502 leukocyte assemblies within the tissue architecture were identified and outlined utilizing Stereologer 503
Software (Stereo Investigator 6, MBF Bioscience, Williams, VT, USA). Percentage of leukocyte 504 covered area has been set in proportion to total area of the analyzed colon section. For the IL-10 505 experiment, hematoxilin stained colon slices were examined by an expert pathologist blinded to 506 treatment conditions. A score of 0-3 was assigned to each section for each of the 3 layers lamina 507
propria, submucosa and muscularis based on the degree of inflammatory infiltration. A score of 0 508 denoted no inflammation and a score of 3 indicated extensive infiltration. The mean of the values for 509 all 3 layers was taken as the final measure of leukocyte infiltration per mouse. 510 511
Quantification of αSyn/Iba1 double positive macrophages 512
The number of α-syn+/Iba1+ positive cells was evaluated by quantification of 10 random regions in 2 513 adjacent sections of the proximal colon. The region of interest was set to contain the myenteric 514 plexus/circular muscle layer and the submucosal plexus. Cells were assessed for positive αSyn 515 staining and concomitant co-localization with the macrophage marker Iba1 was quantified. 516 517
Scoring of pSer129 pathology and brain heatmap 518
We evaluated pSer129 pathology on a full series of immunostained coronal sections from 10 mice per 519 treatment group (i.e. water vs. DSS-treated groups) on blind-coded slides using a previously described 520 method 74 . We visualized pathology from one hemisphere of all brain sections (apart from the 521 olfactory area) using NIKON Eclipse Ni-U microscope and assigned scores ranging from 0 to 4 to 522
Page 21/43 each brain area based on the relative abundance of PK-resistant pSer129-positive inclusions (i.e. cell 523 bodies and neurites). In this case, 0 = no aggregates, 1 = sparse, 2 = mild, 3= dense, 4 = very dense. 524
For the heatmap, we obtained the average score values of each brain area for each treatment group. 525
The average data for each treatment group (n=10/ group) was then represented as a heatmap in a 526 sagittal mouse brain background (http://atlas.brain-527 map.org/atlas?atlas=2#atlas=2&structure=771&resolution=16.75&x= 528
7755.7470703125&y=3899.625&zoom=-3&plate=100883867&z=5). 529 530
Densitometry of pSer129 αSyn brain pathology 531
The density of pSer129 pathology in 12 major brain areas (reticular nucleus, pontine reticular nucleus, 532 periaqueductal gray, gray and white layer, reticular formation, substantia nigra, ventral tegmental 533 area, thalamus, hypothalamus, central amygdala, pallidum and striatum) was determined in the water 534 and DSS-treated animals. A NIKON Eclipse Ni-U microscope was used to acquire 20x magnification 535 images (without condenser lens) from all the indicated brain areas, using the same exposure time for 536 all images. In all cases, images were acquired on three sections separated by 420 μm intervals 537 (localized between Bregma). We then processed the acquired images using Image J64
75
, created a 538 mask (to exclude background) that redirects to the original image for analysis, measured the total area 539 and the mean grey value of the area that had inclusions. For brain areas such as periaqueductal gray 540 that do not fill the entirety of the field to be analyzed, we drew a contour of the area and the analysis 541 was performed only within that contoured area. We subsequently calculated the grey value of the area 542 per square pixels for each image (i.e. A.U./px 2 = mean grey value x area stained/total area assessed). 543
Based on this, we calculated the average grey value per square pixels for each brain area for each 544 animal (n = 6 mice/group), and then extended this calculation to determine the average grey value per 545 square pixels for each treatment group and each of the twelve brain areas of interest. the pSer129 αSyn cell count dataset, an offset for the total area examined was included to model the 567 densities. Linear contrasts with false discovery rate (FDR) adjustments were then used to test our 568 hypotheses and account for multiple testing (for brain area and experimental group). Like the pSer129 569 dataset, the Iba-1/αSyn-double positive dataset were analyzed using negative-binomial regression and 570
Tukey HSD adjusted contrasts to test our hypotheses. . 576
Statistical analyses to assess the effect of the experimental conditions on the log2 gene expression 577 levels were done with linear models using the limma package (Bioconductor/R, Smyth, 2005). These 578 analyses were implemented in R v3.1.1. 579
580
For the statistical modelling of the effects of the IL-10 treatment on αSyn counts, as well as 581 infiltration scores, the levels for IgG1(v1)-IL10 and IgG1(v2)-IL10 treatment were compared to the 582 positive (vehicle/DSS) control. Additionally, since levels of the control antibody treatment (IgG1(v1)) 583
were very similar to the positive control, the two groups were pooled in further contrasts in which 584 effects of individual antibodies or control IgG was assessed. For αSyn counts, a linear model on the 585 treatment groups with one-degree freedom contrasts was applied. For the infiltration score a Kruskal-586
Wallis test, with the same contrasts, was used. 587
588
Study approvals 589
The human subjects' study was conducted with the approval of the local Ethical Committee in Bern 
